Ischemic benefit vs. hemorrhagic risk in the THALES dual antiplatelet therapy trial скачать в хорошем качестве

Ischemic benefit vs. hemorrhagic risk in the THALES dual antiplatelet therapy trial

S. Claiborne Johnston, MD, PhD, Dell Medical School, The University of Texas at Austin, Austin, TX, shares an update on the latest risk and benefit findings in the THALES trial, investigating the use of ticagrelor plus aspirin versus aspirin alone in patients with mild-to-moderate acute noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). Previously reported primary results demonstrated a reduction of ischemic events with the use of dual antiplatelet therapy, but also an increase in the risk of major hemorrhage. To better understand the benefit and risk findings, net clinical impact was determined, defined as the combination of major ischemic events and major hemorrhage. Net clinical impact favored ticagrelor-aspirin, with a reduction of four major ischemic events for every one increase in major hemorrhage. This interview took place at the European Stroke Organisation Conference (ESOC), 2021.